NYSE:TAK - Takeda Pharmaceutical Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$17.06
▲ +0.14 (0.83%)
1 month | 3 months | 12 months
Get New Takeda Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TAK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TAK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Takeda Pharmaceutical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $17.06.
Hold
The current consensus among 2 contributing investment analysts is to hold stock in Takeda Pharmaceutical. This rating has held steady since August 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2021JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
i
4/5/2021Jefferies Financial GroupDowngradeBuy ➝ HoldLow
i
3/11/2020JPMorgan Chase & Co.Lower Price TargetOverweight$31.00 ➝ $30.00Low
i
11/1/2019CowenInitiated CoverageMarket Perform$19.50High
i
9/24/2019Jefferies Financial GroupInitiated CoverageBuyLow
i
8/15/2019Daiwa Capital MarketsDowngradeOutperform ➝ NeutralLow
i
3/19/2019The Goldman Sachs GroupReiterated RatingBuyMedium
i
(Data available from 4/22/2016 forward)
Takeda Pharmaceutical logo
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; and strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Read More

Today's Range

Now: $17.06
$17.06
$17.12

50 Day Range

MA: $18.21
$16.84
$19.90

52 Week Range

Now: $17.06
$15.30
$20.00

Volume

30,428 shs

Average Volume

3,805,114 shs

Market Capitalization

$53.84 billion

P/E Ratio

56.87

Dividend Yield

4.28%

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Takeda Pharmaceutical?

The following Wall Street analysts have issued reports on Takeda Pharmaceutical in the last year: Jefferies Financial Group Inc., JPMorgan Chase & Co., and Zacks Investment Research.
View the latest analyst ratings for TAK.

What is the current price target for Takeda Pharmaceutical?

0 Wall Street analysts have set twelve-month price targets for Takeda Pharmaceutical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Takeda Pharmaceutical in the next year.
View the latest price targets for TAK.

What is the current consensus analyst rating for Takeda Pharmaceutical?

Takeda Pharmaceutical currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TAK, but not buy more shares or sell existing shares.
View the latest ratings for TAK.

What other companies compete with Takeda Pharmaceutical?

How do I contact Takeda Pharmaceutical's investor relations team?

Takeda Pharmaceutical's physical mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company's listed phone number is 813-3278-2111. The official website for Takeda Pharmaceutical is www.takeda.com.